[go: up one dir, main page]

MX2015015073A - Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona. - Google Patents

Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona.

Info

Publication number
MX2015015073A
MX2015015073A MX2015015073A MX2015015073A MX2015015073A MX 2015015073 A MX2015015073 A MX 2015015073A MX 2015015073 A MX2015015073 A MX 2015015073A MX 2015015073 A MX2015015073 A MX 2015015073A MX 2015015073 A MX2015015073 A MX 2015015073A
Authority
MX
Mexico
Prior art keywords
oxoquinazolin
dione
amino
methyl
piperidine
Prior art date
Application number
MX2015015073A
Other languages
English (en)
Other versions
MX363652B (es
Inventor
Hon-Wah Man
Benjamin M Cohen
William W Leong
Alexander L Ruchelman
Matthew M Kreilein
Anusuya Choudhury
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2015015073A publication Critical patent/MX2015015073A/es
Publication of MX363652B publication Critical patent/MX363652B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se proporcionan en la presente procesos para la preparación de 3- (5-amino-2-metil-4-oxoquinazolin-3(4H) - il)piperidin-2,6-diona, o un enantiómero o una mezcla de enantiómeros de los mismos; o una sal farmacéuticamente aceptable de los mismos.
MX2015015073A 2013-05-01 2014-04-30 Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona. MX363652B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818254P 2013-05-01 2013-05-01
PCT/US2014/036083 WO2014179416A1 (en) 2013-05-01 2014-04-30 Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione

Publications (2)

Publication Number Publication Date
MX2015015073A true MX2015015073A (es) 2016-03-03
MX363652B MX363652B (es) 2019-03-28

Family

ID=50885008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015073A MX363652B (es) 2013-05-01 2014-04-30 Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona.

Country Status (26)

Country Link
US (3) US9067912B2 (es)
EP (2) EP3199532A1 (es)
JP (2) JP6490055B2 (es)
KR (1) KR20160003228A (es)
CN (2) CN107935994A (es)
AR (1) AR096165A1 (es)
AU (2) AU2014260011A1 (es)
CA (1) CA2910971A1 (es)
CY (1) CY1119525T1 (es)
DK (1) DK2991976T3 (es)
ES (1) ES2645944T3 (es)
HR (1) HRP20171535T1 (es)
HU (1) HUE034770T2 (es)
LT (1) LT2991976T (es)
MX (1) MX363652B (es)
NZ (1) NZ628322A (es)
PH (1) PH12015502477A1 (es)
PL (1) PL2991976T3 (es)
PT (1) PT2991976T (es)
RS (1) RS56565B1 (es)
RU (1) RU2015151359A (es)
SG (1) SG11201508836XA (es)
SI (1) SI2991976T1 (es)
SM (1) SMT201700513T1 (es)
TW (1) TW201536766A (es)
WO (1) WO2014179416A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
PL2683708T3 (pl) 2011-03-11 2018-03-30 Celgene Corporation Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania
JP2015531776A (ja) 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
WO2017004532A1 (en) 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
CN106083622B (zh) * 2016-06-16 2018-06-19 常州齐晖药业有限公司 一种甲苯咪唑中间体3,4-二氨基二苯甲酮的制备方法
WO2018165142A1 (en) * 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CN113101295A (zh) * 2020-03-20 2021-07-13 上海疆云医疗健康科技有限公司 二苯乙烯类似物在治疗糖尿病肾脏疾病中的用途
CA3229553A1 (en) * 2021-09-02 2023-03-09 Synthon B.V. A process for making osimertinib

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
HUE035389T2 (en) * 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
SI2683384T1 (sl) * 2011-03-11 2016-05-31 Celgene Corporation Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
PL2683708T3 (pl) * 2011-03-11 2018-03-30 Celgene Corporation Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania
JP2015531776A (ja) * 2012-09-04 2015-11-05 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法
JP6359563B2 (ja) * 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体

Also Published As

Publication number Publication date
CN105377831A (zh) 2016-03-02
AU2014260011A1 (en) 2015-11-12
EP2991976B1 (en) 2017-09-20
AR096165A1 (es) 2015-12-09
DK2991976T3 (da) 2017-11-06
JP6490055B2 (ja) 2019-03-27
CN107935994A (zh) 2018-04-20
PH12015502477A1 (en) 2016-02-22
US20160009685A1 (en) 2016-01-14
US20140330016A1 (en) 2014-11-06
RU2015151359A (ru) 2017-06-06
US9266858B2 (en) 2016-02-23
SG11201508836XA (en) 2015-11-27
US9067912B2 (en) 2015-06-30
PL2991976T3 (pl) 2018-01-31
MX363652B (es) 2019-03-28
NZ628322A (en) 2017-06-30
US9303014B2 (en) 2016-04-05
CN105377831B (zh) 2018-02-02
TW201536766A (zh) 2015-10-01
LT2991976T (lt) 2017-10-25
HRP20171535T1 (hr) 2017-11-17
WO2014179416A1 (en) 2014-11-06
JP2019069958A (ja) 2019-05-09
KR20160003228A (ko) 2016-01-08
CA2910971A1 (en) 2014-11-06
EP2991976A1 (en) 2016-03-09
SMT201700513T1 (it) 2018-01-11
PT2991976T (pt) 2017-11-14
CY1119525T1 (el) 2018-03-07
AU2017200965A1 (en) 2017-03-02
US20150274694A1 (en) 2015-10-01
JP2016517886A (ja) 2016-06-20
ES2645944T3 (es) 2017-12-11
EP3199532A1 (en) 2017-08-02
RS56565B1 (sr) 2018-02-28
HUE034770T2 (hu) 2018-02-28
SI2991976T1 (sl) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2015015073A (es) Sintesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin- 2,6-diona.
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
CY1121592T1 (el) Μια στερεη μορφη της υδροχλωρικης (s)-3-(4-((4-μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο-2,6-διονης
DK2882442T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion
IN2015DN00845A (es)
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
SG11201600996UA (en) Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
EA201600121A1 (ru) Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
WO2012103226A3 (en) Bendamustine formulations
MX2020011641A (es) Proceso novedoso para la preparacion de pirrolidina-dionas espiroheterociclicas.
NZ712341A (en) A crystalline form of an anxiolytic compound
CL2016001745A1 (es) Ácido (s)-3'-metil-abscísico y ésteres del mismo
WO2013008253A3 (en) Imatinib formulations
BR112012007737A2 (pt) processos para a preparação de compostos de 2-(1-feniletil)isoindolin-1-ona
EA201391419A1 (ru) Пролекарства d-изоглутамил-[d/l]-триптофана
CO2019012594A2 (es) Proceso para la preparación de enantiómeros de pirlindol y sus sales
EA201391421A1 (ru) Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
UY37477A (es) Potenciadores de bmp
AR083756A1 (es) Formas solidas del 3-(4-(aminometil)-1-(5-metil-7h-pirrolo[2,3-d]pirimidin-4-il)piperidin-4-carboxamido)fenil dimetilcarbamato
TH1501006617A (th) การสังเคราะห์ 3-(5อะมิโน-2-เมธิล-4-ออกโซควินาโซลิน-3(4h)-อิล)ไพเพอริดีน-2,6-ไดโอน
TH163399A (th) การสังเคราะห์ 3-(5อะมิโน-2-เมธิล-4-ออกโซควินาโซลิน-3(4h)-อิล)ไพเพอริดีน-2,6-ไดโอน
IN2013CH04981A (es)